Literature DB >> 19961902

Effects of nicotine on the amplitude and gating of the auditory P50 and its influence by dopamine D2 receptor gene polymorphism.

V Knott1, A Millar, D Fisher, P Albert.   

Abstract

Evidence of normalized auditory P50 suppression with acute nicotine in schizophrenia has supported the contention that elevated smoking rates in this disorder may be an attempt to correct a nicotinic receptor pathophysiology that may underly impaired sensory gating in these patients. There is very little information regarding the neurochemical or genetic pathways through which nicotine regulates P50 amplitude and its suppression in human studies. In a randomized, double-blind, placebo-controlled design with 24 non-smokers, this study examined the influence of TaqIA dopamine D2 receptor gene polymorphisms on P50 and its inhibition during nicotine gum (6 mg) administration. Within a paired click (S(1)-S(2)) paradigm, placebo treated A1(+) and A1(-) allele groups differed with respect to P50 amplitude and gating. While nicotine (relative to placebo) attenuated S(1) P50 amplitude in A1(+) allele carriers, in the A1(-) carriers it increased S(2) P50 amplitude and increased P50 gating as indexed by an augmented gating difference wave (GDW). These findings suggest that nicotine exerts mixed gating properties in healthy nicotine naive volunteers and that dopamine functions to alter both P50 and its gating as well as their response to acute nicotine agonist treatment. Copyright 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19961902     DOI: 10.1016/j.neuroscience.2009.11.053

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  10 in total

1.  P50 amplitude reduction: a nicotinic receptor-mediated deficit in first-degree relatives of schizophrenia patients.

Authors:  Bruce I Turetsky; Gersham Dent; Judith Jaeger; Stephen R Zukin
Journal:  Psychopharmacology (Berl)       Date:  2011-11-03       Impact factor: 4.530

2.  The moderating role of the dopamine transporter 1 gene on P50 sensory gating and its modulation by nicotine.

Authors:  A Millar; D Smith; J Choueiry; D Fisher; P Albert; V Knott
Journal:  Neuroscience       Date:  2011-02-16       Impact factor: 3.590

3.  The separate and combined effects of monoamine oxidase inhibition and nicotine on P50 sensory gating.

Authors:  Dylan M Smith; Derek Fisher; Pierre Blier; Vadim Illivitsky; Verner Knott
Journal:  Psychopharmacology (Berl)       Date:  2014-12-04       Impact factor: 4.530

4.  Effects of COMT genotype on sensory gating and its modulation by nicotine: Differences in low and high P50 suppressors.

Authors:  S de la Salle; D Smith; J Choueiry; D Impey; T Philippe; H Dort; A Millar; P Albert; V Knott
Journal:  Neuroscience       Date:  2013-03-25       Impact factor: 3.590

5.  Sensory gating in tobacco-naïve cannabis users is unaffected by acute nicotine administration.

Authors:  Ashley M Francis; Andrea Parks; Joëlle Choueiry; Nicole El-Marj; Danielle Impey; Verner J Knott; Derek J Fisher
Journal:  Psychopharmacology (Berl)       Date:  2021-05-01       Impact factor: 4.530

Review 6.  Cognitive Dysfunction, Affective States, and Vulnerability to Nicotine Addiction: A Multifactorial Perspective.

Authors:  Morgane Besson; Benoît Forget
Journal:  Front Psychiatry       Date:  2016-09-21       Impact factor: 4.157

7.  Genetic Determinants of Gating Functions: Do We Get Closer to Understanding Schizophrenia Etiopathogenesis?

Authors:  Rastislav Rovný; Dominika Besterciová; Igor Riečanský
Journal:  Front Psychiatry       Date:  2020-11-25       Impact factor: 4.157

Review 8.  Comparative Analysis of Dopaminergic and Cholinergic Mechanisms of Sensory and Sensorimotor Gating in Healthy Individuals and in Patients With Schizophrenia.

Authors:  Andrey T Proshin
Journal:  Front Behav Neurosci       Date:  2022-06-30       Impact factor: 3.617

9.  Differential modulation of the auditory steady state response and inhibitory gating by chloral hydrate anesthesia.

Authors:  Yuchen Wang; Lanlan Ma; Xuejiao Wang; Ling Qin
Journal:  Sci Rep       Date:  2018-02-27       Impact factor: 4.379

Review 10.  Biomarkers and neuromodulation techniques in substance use disorders.

Authors:  Bettina Habelt; Mahnaz Arvaneh; Nadine Bernhardt; Ivan Minev
Journal:  Bioelectron Med       Date:  2020-02-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.